Svensson Anders, Nouhad Jallo, Cederlund Kerstin, Aspelin Peter, Nyman Ulf, Björk Jonas, Torkel Brismar B
Department of Clinical Science, Intervention and Technology at Karolinska Institutte, Division of Medical Imaging and Technology, Stockholm, Sweden.
Acta Radiol. 2012 Jul;53(6):601-6. doi: 10.1258/ar.2012.120268. Epub 2012 Jul 3.
When the same dose of iodine is given to all patients when performing abdominal computed tomography (CT) there may be a wide inter-individual variation in contrast medium (CM) enhancement of the liver.
To evaluate if any of the measures body height (BH), body mass index (BMI), lean body mass (LBM), ideal body weight (IBW), and body surface area (BSA) correlated better than body weight (BW) with hepatic enhancement, and to compare the enhancement when using iodixanol and iomeprol.
One hundred patients referred for standard three-phase CT examination of abdomen were enrolled. Body weight and height were measured at the time of the CT examination. Forty grams of iodine (iodixanol 320 mg I/mL or iomeprol 400 mg I/mL) was injected at a rate of 1.6 g-I/s, followed by a 50 mL saline flush. The late arterial phase was determined by using a semi-automatic smart prep technique with a scan delay of 20 s. The hepatic parenchymal phase started automatically 25 s after the late arterial phase. CM concentration was estimated by placement of regions of interest in aorta (native and late arterial phase) and in liver (native and parenchymal phase).
BW (r = -0.51 and -0.64), LBM (r = -0.54 and -0.59), and BSA (r = -0.54 and -0.65) showed the best correlation coefficients with aortic and hepatic parenchymal enhancement, respectively, without any significant differences between the measures. Comparing iodixanol and iomeprol there was no significant difference in aortic enhancement. The liver enhancement was significantly higher (P < 0.05) using iodixanol than iomeprol.
To achieve a consistent hepatic enhancement, CM dose may simply be adjusted to body weight instead of using more complicated calculated parameters based on both weight and height.
在进行腹部计算机断层扫描（CT）时，若对所有患者给予相同剂量的碘，肝脏的造影剂（CM）增强情况可能存在较大的个体间差异。
评估身高（BH）、体重指数（BMI）、瘦体重（LBM）、理想体重（IBW）和体表面积（BSA）这些指标中，哪一个与肝脏增强的相关性比体重（BW）更好，并比较使用碘克沙醇和碘美普尔时的增强情况。
纳入100例因腹部标准三期CT检查而转诊的患者。在CT检查时测量体重和身高。以1.6 g-I/s的速率注射40克碘（碘克沙醇320 mg I/mL或碘美普尔400 mg I/mL），随后用50 mL生理盐水冲洗。采用半自动智能预扫描技术确定延迟20 s扫描的晚期动脉期。肝实质期在晚期动脉期后25 s自动开始。通过在主动脉（平扫期和晚期动脉期）和肝脏（平扫期和实质期）设置感兴趣区来估计CM浓度。
BW（r = -0.51和-0.64）、LBM（r = -0.
